Interpretation of NCCN clinical practice guidelines for primary central nervous system lymphoma

CUI Xiang-li,ZHANG Guo-bin,ZHANG Zhe,REN Xiao-hui,XU Fei-fan,LIN Song

DOI: https://doi.org/10.3969/j.issn.1009-153X.2013.08.007

2013-01-01

Abstract:Objective To provide references of the standard treatment of primary central nervous system lymphoma (PCNSL) for neurosurgeons in China. Methods The thorough interpretation was performed on the clinical practice guidelines (version 1. 2012) for PCNSL which was made by National Comprehensive Cancer Network (NCCN). Results According to NCCN guidelines, four steps that were initial evaluation, staging workup, initial treatment and treatment at the progressive stage were recommended for treatment of PCNSL. The initial evaluation was to make a definite diagnosis and the neuroimaging performed under conditions without use of steroids was very important to the definite diagnosis. The staging workup was to evaluate the condition of the whole body. According to the guidelines, high-dose methotrexate was recommended for the initial treatment of PCNSL with KPS score ≥ 40 or creatinine clearance rate ≥ 50mL/min and the steroids or whole brain radiotherapy was recommended for the initial treatment of PCNSL with KPS score <40 or creatinine clearance rate <50mL/min. For treatment at the progressive stage of PCNSL, the high-dose methotrexate or whole brain radiotherapy should be chosen according to the specific conditions of the patients. The median survival time ranged from 33 to 60 months in patients with PCNSL treated according to the NCCN guideline. Conclusions The high-dose methotrexate is the first-line choice for treatment of PCNSL and whole brain radiotherapy is the adjuvant treatment according to the NCCN guidelines. It is very important to treat PCNSL according to the NCCN guidelines in order to increase the survival time of patients with PCNSL.